Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.

XSSC:605016 Stock Report

Market Cap: CN¥6.8b

Shandong Bailong Chuangyuan Bio-Tech Past Earnings Performance

Past criteria checks 4/6

Shandong Bailong Chuangyuan Bio-Tech has been growing earnings at an average annual rate of 23.2%, while the Food industry saw earnings growing at 0.6% annually. Revenues have been growing at an average rate of 18.4% per year. Shandong Bailong Chuangyuan Bio-Tech's return on equity is 14.6%, and it has net margins of 21.3%.

Key information

23.2%

Earnings growth rate

16.5%

EPS growth rate

Food Industry Growth7.2%
Revenue growth rate18.4%
Return on equity14.6%
Net Margin21.3%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shandong Bailong Chuangyuan Bio-Tech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSSC:605016 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 241,1522466844
30 Sep 241,0352346033
30 Jun 249872215837
31 Mar 249262025533
31 Dec 238681935033
30 Sep 238251745231
30 Jun 237421635127
31 Mar 237191543330
31 Dec 227221515027
30 Sep 227321474631
30 Jun 227391314532
31 Mar 227171285327
31 Dec 216531044323
30 Sep 21605994314
30 Jun 21566973911
31 Mar 21540984213
31 Dec 20500963415
30 Sep 20479933518
30 Jun 20464924018
31 Mar 20416774416
31 Dec 19421834615
31 Dec 18356653311
31 Dec 17311642510
31 Dec 16336652411

Quality Earnings: 605016 has high quality earnings.

Growing Profit Margin: 605016's current net profit margins (21.3%) are lower than last year (22.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 605016's earnings have grown significantly by 23.2% per year over the past 5 years.

Accelerating Growth: 605016's earnings growth over the past year (27.3%) exceeds its 5-year average (23.2% per year).

Earnings vs Industry: 605016 earnings growth over the past year (27.3%) exceeded the Food industry -8%.


Return on Equity

High ROE: 605016's Return on Equity (14.6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/04 06:04
End of Day Share Price 2025/04/30 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Cong WangCitic Securities Co., Ltd.
Lin YangGuosen Securities Co., Ltd.
Wei LiuHaitong International Research Limited